- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04944641
Epilepsy Prevalence and Intervention Study in Zhejiang Province, China
July 13, 2021 updated by: Second Affiliated Hospital, School of Medicine, Zhejiang University
To carry out the epidemiological investigation on epilepsy in Zhejiang Province, China, and then establish early comprehensive intervention to help patients with epilepsy to improve seizure control and the quality of life.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
To carry out the epidemiological investigation on epilepsy in Zhejiang Province, China, and then establish early comprehensive intervention(proper antiepileptic drugs and education intervention) to help patients with epilepsy to improve seizure control and the quality of life.
Study Type
Interventional
Enrollment (Anticipated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mei-ping Ding
- Phone Number: 13588058581
- Email: dmp-neurology@zju.edu.cn
Study Locations
-
-
-
Shengzhou, China
- Completed
- Shengzhou People's Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
-
Contact:
- Mei-ping Ding
- Phone Number: 13588058581
- Email: dmp-neurology@zju.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Newly diagnosed and untreated epilepsy; Aged 14 and above; Sign the informed consents.
Exclusion Criteria:
With intellectual development disorder; With serious heart and lung diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: A: Routine AED group
Routine and proper antiepileptic drugs group
|
routine and proper antiepileptic drugs
|
|
EXPERIMENTAL: B: AED and education group
Routine, proper antiepileptic drugs and education group
|
routine and proper antiepileptic drugs
education on epilepsy, including epilepsy diary, pamphlet,discussion between patients and phone visits and so on
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline seizures frequency 1
Time Frame: 12 months
|
change from baseline seizures frequency at 12 months, seizure frequency is defined as the number of seizure attacks during 3 months before baseline or endpoint)
|
12 months
|
|
Change from baseline seizures frequency 2
Time Frame: 24 months
|
change from baseline seizures frequency at 24 months, seizure frequency is defined as the number of seizure attacks during 3 months before baseline or endpoint)
|
24 months
|
|
Occurrence of refractory epilepsy
Time Frame: 24 months
|
occurrence of refractory epilepsy at 24 months
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quality of life (QOL scales)
Time Frame: 2 year
|
Quality of Life Scale, high scores mean a better outcome
|
2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
September 13, 2013
Primary Completion (ANTICIPATED)
September 30, 2022
Study Completion (ANTICIPATED)
December 31, 2022
Study Registration Dates
First Submitted
June 8, 2021
First Submitted That Met QC Criteria
June 21, 2021
First Posted (ACTUAL)
June 29, 2021
Study Record Updates
Last Update Posted (ACTUAL)
July 19, 2021
Last Update Submitted That Met QC Criteria
July 13, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-032
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.